Metabolic liver disease in HIV-infected people research hub

Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load

This study looks at how well a specific HIV treatment helps people with both HIV and liver problems. It compares a new medicine combination to standard treatments to see if it improves liver health over 18 months.